Mölnlycke Health Care, a global leader in MedTech, has confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK.
The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
Building on recent expansion announcements in Brunswick, USA, and Changshu, China, the coordinated investments reflect Mölnlycke’s continued focus on meeting growing demand for advanced wound care solutions and helping to free patients from the burden of wounds, while optimising its manufacturing footprint.
Scaling capacity and efficiency in Finland
At its Mikkeli site, Mölnlycke is investing in expanded sterilisation and production capabilities. The programme doubles sterilisation capacity and introduces an advanced ‘soft cycle’ process, ensuring gentler product treatment and more sustainable manufacturing processes.
This expansion also increases manufacturing capacity by around 100 million units annually, an increase of nearly 50%, supported by a new production line with automated inline packaging and cartoning to improve efficiency and handling.
Strengthening resilience in the UK
In parallel, Mölnlycke has inaugurated new state-of-the-art clean room and packaging facilities in Oldham, expanding UK manufacturing capacity.
Moreover, by bringing sterilisation closer to production, Mölnlycke expects to shorten lead times by around one week while reducing transportation distances and emissions, strengthening supply chain resilience and environmental performance.
“Together, these investments strengthen our global wound care manufacturing network and connect capabilities across sites, enabling us to scale efficiently, improve resilience and deliver sustainable growth,” said David Butler, Global Vice President, Operations Wound Care at Mölnlycke.
